Joseph Taylor

Joseph Taylor

Auto-generated profile, based on publicly available information

Joseph Taylor

Precision Health University Research Institute, Queen Mary University of London, London, UK; Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, UK

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
JTJoseph G. Taylor
Joseph G. Taylor
JGJohn G. Gribben
John G. Gribben

18 May 2015 in Biomarkers in Medicine
Verified
Journal Article
Closed access
JTJoseph G Taylor
Joseph G Taylor
KLKonstantinos Liapis
Konstantinos Liapis
JGJohn G Gribben
John G Gribben
There has been considerable interest in the role of the lymphoma microenvironment. Despite the use of highly active antiretroviral therapy (HAART), AIDS-related diffuse large-B-cell lymphoma remain...

31 December 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
JTJoseph G. Taylor
Joseph G. Taylor
ACAndrew Clear
Andrew Clear
MCMaria Calaminici
Maria Calaminici
JGJohn G. Gribben
John G. Gribben
We read with interest the recent paper published in Haematologica by Sasse et al . examining programmed cell death protein – 1 (PD1) expression in paired pretreatment/relapse samples for patients receiving PD1 inhibitor therapy in classical Hodgkin lymphoma (CHL).[1][1] Although the authors

22 December 2025 in eJHaem
Verified
Journal Article
Open access
JTJoseph Taylor
Joseph Taylor
TLTasneem Lakum
Tasneem Lakum
SBShaun Bevan
Shaun Bevan
TFTanya Freeman
Tanya Freeman
JBJesca Boot
Jesca Boot
TFTimothy Farren
Timothy Farren
Background: Molecular T‐cell receptor (TCR) clonality testing cannot link clonality to immunophenotype, limiting discrimination between malignant and clonal reactive T‐cell expansions. Methods: We evaluated TRBC1/TRBC2 immunophenotyping in 50 consecutive cases with suspected T‐cell malignancy, assessing restriction (ratio > 10) across T‐cell subsets. Results: TRBC immunophenotyping showed 100% sensitivity for T‐cell malignancy if assessed within subsets or phenotypically abnormal populations. Malignant clones predominantly showed CD4αβ/CD8αβ restriction (18/21), while reactive clones predominantly showed γδ/dual‐positive/dual‐negative restriction (15/16), enabling enhanced discrimination. Conclusion: TRBC immunophenotyping provides sensitive clonality detection with phenotypic lineage assignment, adding diagnostic clarity beyond molecular testing and supporting integration into routine workflows. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.

27 June 2026 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
MNMichael Neale
Michael Neale
CWCynthia Wong
Cynthia Wong
DKDaniel Kreuter
Daniel Kreuter
JTJoseph Taylor
Joseph Taylor
SSSuthesh Sivapalaratnam
Suthesh Sivapalaratnam

20 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DKDaniel Kreuter
Daniel Kreuter
JTJoseph Taylor
Joseph Taylor
SDSimon Deltadahl
Simon Deltadahl
MBMartin Besser
Martin Besser
JBJohn R Bradley
John R Bradley
MRMichael Roberts
Michael Roberts
Iron deficiency (ID) is a major contributor to global disease burden and the leading cause of anaemia. Early detection is important for proactive management, but conventional complete blood count (CBC) screening often fails to identify non-anaemic iron deficiency (NAID) as many individuals maintain haemoglobin and red cell indices within reference ranges. Analysing 153,565 subjects from the INTERVAL, COMPARE and STRIDES studies, we show that CBC screening has only 40.5 % sensitivity for ID detection, falling to 21.9 % for NAID, highlighting a detection gap. CBC analysers generate a wealth of data beyond Electronic Health Record CBC parameters. We demonstrate that artificial intelligence applied to single-cell flow cytometry data from the CBC analyser achieves 83.7 % sensitivity for ID and 79.3 % for NAID. Our findings show that AI can greatly improve detection of a high-prevalence, important condition without changing infrastructure or diagnostic pathways, providing a valuable tool for proactive anaemia management.